BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29333087)

  • 21. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
    Sun H; Zeng J; Miao Z; Lei KC; Huang C; Hu L; Su SM; Chan UI; Miao K; Zhang X; Zhang A; Guo S; Chen S; Meng Y; Deng M; Hao W; Lei H; Lin Y; Yang Z; Tang D; Wong KH; Zhang XD; Xu X; Deng CX
    Theranostics; 2021; 11(20):9967-9987. PubMed ID: 34815798
    [No Abstract]   [Full Text] [Related]  

  • 22. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
    Larsen MJ; Thomassen M; Tan Q; Lænkholm AV; Bak M; Sørensen KP; Andersen MK; Kruse TA; Gerdes AM
    BMC Med Genomics; 2014 Jan; 7():9. PubMed ID: 24479546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
    Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
    Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
    Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
    Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
    Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.
    Shao B; Feng Y; Zhang H; Yu F; Li Q; Tan C; Xu H; Ying J; Li L; Yang D; Peng W; Tang J; Li S; Ren G; Tao Q; Xiang T
    J Cell Mol Med; 2018 Feb; 22(2):1257-1271. PubMed ID: 29193730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study on the mechanism of heterogeneous tumor-associated macrophages in three subtypes of breast cancer through the integration of single-cell RNA sequencing and in vitro experiments.
    Yuan Y; Zhang S; Huang J
    Mol Biol Rep; 2024 Jun; 51(1):720. PubMed ID: 38824268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
    Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
    Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
    Massink MP; Kooi IE; van Mil SE; Jordanova ES; Ameziane N; Dorsman JC; van Beek DM; van der Voorn JP; Sie D; Ylstra B; van Deurzen CH; Martens JW; Smid M; Sieuwerts AM; de Weerd V; Foekens JA; van den Ouweland AM; van Dyk E; Nederlof PM; Waisfisz Q; Meijers-Heijboer H
    Mol Oncol; 2015 Apr; 9(4):877-88. PubMed ID: 25616998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Regulation of CDH1 Is Altered after HOXB7-Silencing in MDA-MB-468 Triple-Negative Breast Cancer Cells.
    Paço A; Leitão-Castro J; Freitas R
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
    BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
    Joosse SA; Brandwijk KI; Mulder L; Wesseling J; Hannemann J; Nederlof PM
    Genes Chromosomes Cancer; 2011 Feb; 50(2):71-81. PubMed ID: 21104783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
    Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
    Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
    Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.